Caitlin Raymond: Understanding Risks in Rare Group A Subtypes with Anti-A1 Antibodies in Transfusion Medicine
Caitlin Raymond, Assistant Professor of Pathology and Transfusion Medicine at the University of Wisconsin-Madison, shared a post on LinkedIn:
”In transfusion medicine, some risks feel larger than they actually are — not because they’re common, but because the evidence we have is skewed toward worst-case scenarios.
I recently wrote a follow-up blog post on rare group A subtypes with anti-A1 antibodies, prompted by a real case and a conversation with a reference laboratory.
Case reports tell us what can go wrong. Reference labs see what actually does go wrong — and how often.
This post walks through:
- When cold reacting anti-A1 actually becomes dangerous
- Why malignancy-associated cases don’t generalize
- When to choose group O blood for rare group A subtypes
If you’ve ever felt uneasy making decisions where the literature offers warnings but no denominator, this one’s for you.”

Stay updated with Hemostasis Today.
-
Jun 27, 2026, 01:31Alessio De Rose: Addressing Micronutrient Deficiencies in the Era of GLP-1 Receptor Agonists
-
Jun 27, 2026, 01:21Michelle Sámano Sánchez: Exploring Vitamin C as an Adjunct Therapy for Anemia in Hemodialysis
-
Jun 27, 2026, 01:08Ana Raquel Gotine: The First Pragmatic Clinical Trial on MNPs and Childhood Anemia in Mozambique
-
Jun 27, 2026, 00:56Sherif Badawy: Reflecting on My Time with ASH CRTI
-
Jun 27, 2026, 00:48Zain Khalpey: Why High quality CPR is Only Part of Successful Cardiac Arrest Management
-
Jun 26, 2026, 22:31Wendy Dusenbury: The New Issue of the Stroke Clinician is Now Live
-
Jun 26, 2026, 20:42Ed Watson: When It Happens to You, Stroke Becomes Personal, Immediate, and Life-Changing
-
Jun 26, 2026, 19:45Nathan Connell: Transforming Surgical Care with Tranexamic Acid
-
Jun 26, 2026, 18:28Daniel Pereira Monteiro: Why Is Beta Thalassaemia Major so Severe?